Ed Allen

[IsoPet® Cancer Treatment @IsoPetForCancer]

In our efforts to expand across the country @ACVIM is one of the best conferences that we attend as an exhibitor. We have made some incredible veterinarians across the country interested in our innovative, targeted radiation cancer treatment! $RDGL

[Vivos Inc. @VivosIncUSA]

Vivos Inc is pleased to announce the receipt of the Washington State Radioactive Materials License for IsoPet® Manufacturing which clears the way for in-house production at Vivos’ new domestic manufacturing facility. $RDGL https://t.co/SYUj8N0IFb

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL scores a major win: Washington State radioactive materials license secured for domestic IsoPet manufacturing. RadioGel next!

[smiles @doccjc62]

$RDGL Licensing piece reinforces intent and direction .

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL Still under the radar, but 25 days max may change all of that. Bring on the IDE decision.

[smiles @doccjc62]

$RDGL
✅ IDE for RadioGel resubmitted to the FDA today
✅ Top FDA expert Dr. John J. Smith on board
✅ 30 days or less for decision.
Share price hasn’t moved.....yet....🚀🚀🚀

[smiles @doccjc62]

Let's get that IDE approval ! $RDGL

[RDGL INVESTORS GROUP @RDGLinvestors]

IDE resubmitted ! , and this time with the help of a highly qualified FDA consultant . 30 days until decision. 📈📈📈

[Albino Skunk @BillH480045]

@RDGLinvestors

Did we miss this little gem hidden in there $Radiogel website

https://t.co/eca42d7L8l

[IsoPet® Cancer Treatment @IsoPetForCancer]

We are pleased to announce an update to our website! An abstract and presentation from
Johns Hopkins University on the Utilization of Radiopharmaceutical Therapies in Animals with Naturally Occurring Disease. $RDGL
https://t.co/NQx4BtKpYz

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL Past ~month: 61.99 Million shares traded 🔥
Tape readers showing massive buy dominance:

• One day: Buys 6.82M vs Sells 435K

• Another: Buys 3.28M vs Sells 328K

• Multiple days 95:1 or 10-20x+ buys over sells

Quiet accumulation in progress while price holds steady? $RDGL $Biotech

[RDGL INVESTORS GROUP @RDGLinvestors]

🚨 $RDGL at $0.065 / $32M MC
Flying Under the Radar! 📈📈📈

Precision Radionuclide Therapy that targets tumors precisely for both humans and pets.

4 KEY CATALYSTS:

FDA IDE SUBMISSION... Imminent filing for RadioGel→ Human trials at Mayo Clinic on approval. Unlocks massive U.S. market potential.

INDIA HUMAN TRIALS... Ongoing demos showing tumor shrinkage + excellent safety (zero serious side effects). Builds strong global credibility.

IsoPet (Veterinary)... 800%+ growth, 100+ treatments, 17+ clinics expanding. Real revenue ramp into 2026.

PrecisionGel... Patented Y-90 hydrogel + new U.S./India plants in 2026. Ready for licensing & partnerships.

CEO owns over 11 million shares with recent buys.... serious skin in the game.

This tiny-cap biotech is loaded with near-term catalysts. Could be a big runner in 2026. 📈📈📈
$RDGL $RadioGel $IsoPet $Biotech

[RDGL INVESTORS GROUP @RDGLinvestors]

Source: Full Vivos PrecisionGel / Elution Business Update (May 13) → https://t.co/fwGVqFHkex

[Hondo @JimTom44]

$rdgl @VivosIncUSA are working towards and getting primed to take some of that market. @BradWeeks0331

[Hondo @JimTom44]

$rdgl Thankful they brought in Dr. John J. Smith, M.D., J.D., and his team at Hogan Lovells as the company’s lead regulatory advisors for its FDA Investigational Device Exemption (IDE) submission for RadioGel®.
With approval, @VivosIncUSA rockets to a whole new level.

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL MAY BE ONE OF THE MOST OVERLOOKED MICROCAP ONCOLOGY PLAYS RIGHT NOW

$RDGL is trading around $0.065 (~$32M market cap), and looks significantly undervalued relative to its pipeline and catalysts.

Key points:

• RadioGel – targeted radiotherapy platform for solid tumors

• Upcoming IDE submission – major regulatory milestone

• Mayo Clinic involvement for future human trials

• International clinical development efforts in India supporting broader oncology pathway expansion

• IsoPet – veterinary oncology business with strong year-over-year growth in treated cases and expanding adoption

• PrecisionGel – next-gen platform with licensing / partnership opportunities

Multiple shots on goal across human + veterinary oncology, with several near-term catalysts ahead.

Not financial advice ,just a small-cap biotech worth watching closely.

[Vivos Inc. @VivosIncUSA]

Vivos is pleased to report positive independent drug elution data validating PrecisionGel™ for sustained localized delivery of the company’s proprietary PLGA-g-PEG thermogelling hydrogel. $RDGL To read more visit our website https://t.co/XTEjJBqPWS

[RDGL INVESTORS GROUP @RDGLinvestors]

Independent validation of PrecisionGel for sustained localized delivery . Great step forward for $RDGL!

[Hondo @JimTom44]

$rdgl They have a lot going on behind the scene. IDE #1, IsoPet is sneaky huge, PrecisionGel.....and more I'm sure. @VivosIncUSA

[Hondo @JimTom44]

$rdgl "In addition, Vivos is preparing to bring online its new in-house production facility, which is expected to deliver significant improvements in manufacturing efficiency and support scaled treatment of a growing number of patients." https://t.co/lM5UVqx2d4